AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

12 7 2023 07:00:00 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

07 7 2023 07:00:53 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock

30 6 2023 16:02:39 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock

28 6 2023 09:28:25 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

27 6 2023 20:24:44 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

01 6 2023 07:00:30 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

30 5 2023 07:00:54 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

08 5 2023 07:00:16 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference

03 5 2023 07:00:50 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

01 5 2023 07:00:31 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

21 4 2023 07:00:34 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

14 4 2023 07:00:49 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8

13 4 2023 07:00:34 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference

01 3 2023 07:00:01 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

27 2 2023 07:00:00 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

22 2 2023 07:00:01 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference

07 2 2023 07:00:01 提供 Nasdaq GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27

31 1 2023 07:00:00 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

07 12 2022 07:00:00 提供 Nasdaq GlobeNewswire

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

28 11 2022 06:35:00 提供 Nasdaq GlobeNewswire